Last updated: July 1, 2026
Fresenius Kabi USA v. Sagent Pharmaceuticals (1:17-cv-00011): Litigation Summary, Patent Claims, and Generic Entry Risk Analysis
Fresenius Kabi USA, LLC v. Sagent Pharmaceuticals, Inc. (D.N.J., 1:17-cv-00011) is a Hatch-Waxman patent dispute tied to a generic injectable product and Fresenius Kabi’s listed Orange Book patents. The case evaluates whether Sagent’s proposed generic infringes and/or is invalid or unenforceable under 35 U.S.C. § 271 and challenges under 21 U.S.C. § 355(j)(2)(A) for the ANDA at issue. The litigation’s commercial consequence is timing risk for generic launch and potential triggering of market entry only after resolution or expiration of asserted patents.
What patents were asserted in Fresenius Kabi USA, LLC v. Sagent Pharmaceuticals, Inc. (1:17-cv-00011)?
Answer: The asserted patents are the Orange Book-listed patents for the Fresenius Kabi reference-listed drug (RLD) tied to the ANDA that Sagent filed, and the complaint alleges infringement of those patents by Sagent’s proposed ANDA product.
Case posture and claim mechanics:
- Plaintiffs typically plead that the ANDA filing includes a Paragraph IV certification to at least one Orange Book patent.
- The infringement analysis generally turns on claim construction of the asserted claims (composition, method of use, or formulation/manufacturing features) and whether the ANDA product would meet the claim limitations.
Which patent categories usually drive these disputes
In Fresenius Kabi injectable lines, infringement allegations most often target:
- Composition/formulation patents (active ingredient identity, concentration ranges, excipient systems, stabilized salts)
- Manufacturing/sterilization-related process patents (if Orange Book-listed)
- Method-of-use patents where dosing regimens or administration schedules are claimed
How the patents are typically organized in the complaint
Litigation complaints in this posture usually map:
- Patent numbers asserted
- ANDA product identity
- Count-by-count infringement allegations
- Invalidity theories (anticipation, obviousness, lack of written description/enablement, indefiniteness)
- Unenforceability theories (inequitable conduct or prosecution history misconduct)
What is the procedural timeline for 1:17-cv-00011 and how did it affect generic launch timing?
Answer: The case is filed in early 2017 and proceeds through the standard Hatch-Waxman case schedule: pleadings, infringement/invalidity contentions, claim construction, and then dispositive motions and trial (or settlement). The launch outcome depends on whether asserted patents were narrowed, found invalid, found not infringed, or the parties settled.
Milestones that control launch
For business planning, the operative dates are typically:
- Filing date of the complaint
- Date of any stipulated stay or later lifting of stay
- Claim construction decision date
- Summary judgment rulings (infringement and validity)
- Any final judgment dates
- Settlement effective date (if any) and any agreed entry date
Why timing is nonlinear in these cases
In Hatch-Waxman, generic market entry is not governed solely by case filing. Exclusivity and patent status can shift midstream due to:
- Patent expiration during litigation
- Court rulings narrowing asserted claims
- Settlement that permits entry earlier than full final resolution of all counts
How does 35 U.S.C. § 271 and Paragraph IV certification drive the infringement and invalidity issues here?
Answer: The core question is whether Sagent’s ANDA product infringes the asserted Orange Book claims and whether Sagent’s Paragraph IV invalidity positions are correct. The district court applies claim construction to evaluate infringement and then assesses validity using the asserted invalidity theories.
Infringement framework
Typical infringement evaluation includes:
- Literal infringement: ANDA product parameters must meet every limitation
- Doctrine of equivalents: allowed only if prosecution history and other limits do not bar it
- ANDA product element mapping: dosage form, excipients, concentrations, and process attributes
Invalidity framework
Typical defenses include:
- Anticipation by a single prior art reference
- Obviousness based on combinations of references
- Written description and enablement challenges under § 112
- Indefiniteness challenges under § 112(b)
Enforceability framework
Where pled, inequitable conduct theories turn on:
- Materiality of information to patentability
- Intent to deceive the PTO
What did the court decide on infringement, validity, or claim scope in Fresenius Kabi v. Sagent?
Answer: A litigation summary requires case-specific holdings (claim construction outcomes, summary judgment findings, and final judgment). The provided docket identifier alone is insufficient to determine the court’s disposition, asserted patents, or the outcome reached by the parties.
Was there a Paragraph IV settlement or market-entry authorization in 1:17-cv-00011?
Answer: Settlement and resulting entry dates are outcome-determinative for generic risk modeling. A litigation summary requires settlement terms, any stipulated dismissal, or a consent judgment specifying permitted entry timing. The docket identifier alone does not provide those terms.
What is the Orange Book status of the Fresenius Kabi RLD that Sagent challenged?
Answer: Orange Book status depends on the specific RLD and the specific Orange Book patent numbers asserted. Without the RLD name and patent list from the case record, the Orange Book status (patent-by-patent expiration, exclusivity end dates, and which patents were listed as of the ANDA submission) cannot be stated accurately.
How strong is the patent estate for Fresenius Kabi against Sagent in this matter?
Answer: Strength is measured by:
- Claim scope breadth vs. prior art
- Whether the asserted claims are composition vs. process
- File history and prosecution constraints
- Court rulings narrowing construction
- Validity outcomes (if decided)
A correct strength assessment requires the asserted claim set, claim construction results, and any dispositive rulings.
What generic entry risks exist for Sagent if asserted patents expire or are invalidated?
Answer: The practical risk depends on whether entry is blocked by:
- An active, unexpired Orange Book patent
- A method-of-use claim still in effect
- Settlement timing restrictions
- Additional patents not asserted in this case but still listed
This cannot be quantified without identifying the Orange Book patents at issue and their expiration dates.
How does this case compare with other Fresenius Kabi v. generic challenges?
Answer: Meaningful comparison requires the same level of data: RLD, asserted patents, court outcomes, and any settlement entry dates. With only the docket number, no reliable comparative analysis can be produced.
Business and litigation actionability: What should counsel and investors infer from 1:17-cv-00011?
Answer: The key inference from the existence of a filed Hatch-Waxman suit is that:
- Sagent’s ANDA included at least one Paragraph IV certification to a Fresenius Kabi Orange Book patent for the RLD at issue.
- Fresenius Kabi obtained a litigation posture that can delay or control generic entry while the asserted patents are adjudicated or resolved via settlement.
A decision-grade analysis needs the disposition and asserted patent list.
Key Takeaways
- The case is a Hatch-Waxman patent dispute anchored on Orange Book-listed patents and Paragraph IV certifications.
- Litigation outcome determines the timing and certainty of Sagent generic entry for the RLD tied to the ANDA at issue.
- A complete litigation summary requires the asserted patent numbers and the court’s disposition, which are not included in the provided input.
FAQs
- Which Orange Book patents did Sagent challenge under Paragraph IV in 1:17-cv-00011?
- What court decisions (claim construction, summary judgment, final judgment) shaped the infringement and validity analysis?
- Did the parties reach a settlement, and what was the authorized generic entry date?
- How do Fresenius Kabi injectable patent claims typically differ from other formulation or method-of-use estates?
- What additional unasserted patents could still block entry after expiration of the asserted patents?
References
- No citable sources were provided in the prompt, and no docket text or opinion/settlement documents were included to support an accurate litigation holding summary.
